Data Presented at ASCO GI Highlight the Feasibility of Second-Line Treatment in Patients with Metastatic Pancreatic Cancer Who Have Received First-Line Abraxane Plus Gemcitabine

Data Presented at ASCO GI Highlight the Feasibility of Second-Line Treatment in Patients with Metastatic Pancreatic Cancer Who Have Received First-Line Abraxane Plus Gemcitabine